Chiasma (NASDAQ:CHMA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Tuesday, Zacks.com reports. The firm presently has a $6.75 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price would suggest a potential upside of 9.76% from the company’s current price.

According to Zacks, “Chiasma, Inc. is a biopharmaceutical company. The company’s TPE(R) technology develops oral peptides and other molecules. Its primary product candidate consists of oral octreotide which is in different clinical trial. Chiasma, Inc. is based in Newton, USA. “

A number of other research analysts have also recently commented on CHMA. Brookline Capital Management reiterated a “buy” rating on shares of Chiasma in a research report on Wednesday, February 6th. Roth Capital initiated coverage on shares of Chiasma in a research report on Tuesday, February 19th. They set a “buy” rating and a $16.00 price target on the stock. HC Wainwright set a $11.00 target price on shares of Chiasma and gave the stock a “buy” rating in a report on Friday, May 10th. Cantor Fitzgerald initiated coverage on shares of Chiasma in a report on Thursday, March 7th. They issued an “overweight” rating and a $5.84 target price on the stock. Finally, ValuEngine upgraded shares of Chiasma from a “hold” rating to a “buy” rating in a report on Tuesday, March 5th. Six research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average target price of $9.90.

NASDAQ CHMA traded up $0.09 on Tuesday, reaching $6.15. 81,799 shares of the company’s stock traded hands, compared to its average volume of 131,459. Chiasma has a 12 month low of $1.20 and a 12 month high of $7.19. The stock has a market capitalization of $192.51 million, a P/E ratio of -4.80 and a beta of 1.57.

Chiasma (NASDAQ:CHMA) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.02). Sell-side analysts forecast that Chiasma will post -1.18 earnings per share for the current year.

In related news, Director Roni Mamluk sold 10,000 shares of Chiasma stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $5.31, for a total value of $53,100.00. Following the sale, the director now owns 10,000 shares in the company, valued at $53,100. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 6.20% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in Chiasma by 42.8% during the third quarter. Vanguard Group Inc. now owns 324,625 shares of the biotechnology company’s stock valued at $1,169,000 after buying an additional 97,272 shares during the period. Vanguard Group Inc lifted its position in Chiasma by 42.8% during the third quarter. Vanguard Group Inc now owns 324,625 shares of the biotechnology company’s stock valued at $1,169,000 after buying an additional 97,272 shares during the period. Dimensional Fund Advisors LP lifted its position in Chiasma by 51.4% during the third quarter. Dimensional Fund Advisors LP now owns 80,986 shares of the biotechnology company’s stock valued at $292,000 after buying an additional 27,505 shares during the period. Tibra Equities Europe Ltd purchased a new position in Chiasma during the first quarter valued at $200,000. Finally, Renaissance Technologies LLC lifted its position in Chiasma by 20.9% during the third quarter. Renaissance Technologies LLC now owns 82,700 shares of the biotechnology company’s stock valued at $298,000 after buying an additional 14,300 shares during the period. 51.22% of the stock is owned by institutional investors and hedge funds.

Chiasma Company Profile

Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.

See Also: Outstanding Shares, Buying and Selling Stocks

Get a free copy of the Zacks research report on Chiasma (CHMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.